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We read with interest Dr. Włodarczyk and Professor 
Kuz ̇dz ̇ał’s appraisal of the potential for composite positron 
emission tomography-computed tomography (PET-CT) 
metrics to improve the assessment of oesophageal cancer to 
neoadjuvant therapy, in particular that of a new metric we 
recently described: metabolic nodal response (mNR) (1,2). 
Our colleagues highlight the goal of precision oncology 
for oesophageal cancer: tailoring therapies to patients. 
At present, whilst neoadjuvant therapy improves survival 
for patients overall (3), this is not necessarily true for 
patients individually. Unfortunately, those with relatively 
chemo- and radio-resistant tumours may actually come to 
harm, as ultimately futile therapy merely delays surgery 
and risks toxicity. However, in the absence of markers to 
identify these patients we are forced to continue with well-
intentioned but largely imprecise oncology. 
The reasons precision oncology has largely failed 
to translate in vitro reports to in vivo success (other 
than relatively isolated therapies targeted to individual 
gene mutations and copy numbers) are numerous (4). 
These include highly complex molecular interactions in 
individual cancer cells (genetic, epigenetic, transcriptomic, 
proteomic), compounded by cellular interactions, tumour 
microenvironment, clonal heterogeneity, and tumour 
evolution during therapy (5). As a consequence, the effect 
sizes of these markers tend to be limited, and certainly an 
insufficient basis on which to decide whether to give or omit 
specific therapies (6).
We are therefore forced to rely on surrogates of response, 
such as metabolic response using serial 18F-FDG PET-CT. 
As our colleagues discuss, Lordick et al. notably described 
interval assessment of oesophageal cancer during neoadjuvant 
chemotherapy, aborting or continuing therapy on the basis 
of whether the primary tumour demonstrated a metabolic 
response on PET-CT, as evidenced by a reduction in avidity 
alone (7). This approach has yet to be adopted for a number 
of reasons, including concerns regarding the inherent 
limitations of PET-CT to accurately reflect the viability and 
metastatic potential of tumour cells, as well as the pragmatic 
but somewhat arbitrary dichotomisation of response (which 
in reality occupies a spectrum). In the paper our colleagues 
discuss, we assessed the relative performance of a number 
of additional PET-CT metrics in a cohort of patients with 
oesophageal cancer receiving neoadjuvant chemotherapy. 
We found that whilst composite spatial-avidity metrics of 
metabolic tumour response (mTR; such as metabolic or 
tumour glycolytic volume) appeared to have greater predictive 
accuracy than avidity alone, this was by no means a perfect 
surrogate for pathological tumour response (pTR). We noted 
that the primary tumour and nodal tumour often responded 
differently, and subsequently found mNR (but not mTR) 
to be an independent predictor of prognosis, once pTR 
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was considered (1). This makes sense, as logically response 
of the primary tumour to neoadjuvant therapy is relevant 
primarily in terms of facilitating a clear (R0) resection, and 
secondarily as a surrogate of therapy sensitivity of any occult 
metastases. However, the primary tumour overall may be 
very different to the metastatic clones responsible for these 
metastases, in contrast to nodal tumour. We therefore believe 
that mNR provides valuable surrogate information regarding 
the phenotype of these metastatic clones, which crucially are 
responsible for the vast majority of post-operative recurrences.
However, beyond the limitations in our study discussed 
by our colleagues, we acknowledge mNR to suffer the 
same failings as mTR: unphysiological thresholding of 
responses, and not infrequent disagreement between 
metabolic and pathological response. Further complicating 
issues are the subjectivity inherent in pTR assessment (8), 
and whether a homogenous microscopic assessment truly 
reflects the different phenotypes within a cancer. Indeed, we 
previously reported a novel concept of genetic response of 
oesophageal adenocarcinoma to neoadjuvant chemotherapy 
(as evidenced by next generation sequencing). This was 
generally concordant with pathological response, but with 
some notable exceptions suggesting some tumours exhibit 
a profound response, followed by rapid overgrowth by a 
marginal clone which was not captured using traditional 
radiological or pathological response assessment (5). 
Ultimately, assessment of these many facets of response 
in parallel may allow us to quantify response better during 
therapy (e.g., serial biopsy with molecular assessment of 
the primary tumour and circulating DNA, along with 
cross-sectional and functional response using PET-CT). 
However, until we have the ability to do so, as our 
colleagues suggest both composite avidity-spatial PET-CT 
metrics of the primary tumour plus mNR may better be 
able to direct therapy for patients in clinical trials.
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